Ahmad Tarhini, MD
Enriched profileDirector, Cutaneous Clinical and Translational Research · H. Lee Moffitt Cancer Center & Research Institute
Ahmad Tarhini is Director, Cutaneous Clinical and Translational Research at H. Lee Moffitt Cancer Center & Research Institute. OpenAlex indexes 874 publications with 16,028 citations (h-index 63); ClinicalTrials.gov lists 27 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 21 Oct 2026
Overview
Updated 23 Oct 2026
Ahmad Tarhini, MD, is Director, Cutaneous Clinical and Translational Research at H. Lee Moffitt Cancer Center & Research Institute. The public record shows 874 publications with 16,028 citations (h-index 63), centered on Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways. It also documents an investigator role on 27 registered clinical trials, industry payments reported by 16 companies, 1 NIH-funded awards (2013–2017).
- Most recent indexed publication: 2026 · Journal for immunotherapy of cancer
- Top research focus: Cancer Immunotherapy and Biomarkers
- 27 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 40 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 180.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 27 registered studies on ClinicalTrials.gov. The most recent:
- Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Sponsor: Nested Therapeutics, Inc
- Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Industry payments
Updated 23 Oct 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year202515 payments$29,714openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year20256 payments
- ModernaTX, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Opioid Agonist100%Oxycodone Hcl100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
1 NIH research award on record, funded 2013–2017 per NIH RePORTER. The latest:
- Biomarkers of the Proinflammatory Response and Elements of Immune Suppression
University of Pittsburgh at Pittsburgh
FY2017$292,902P50CA121973 - Biomarkers of the Proinflammatory Response and Elements of Immune Suppression
University of Pittsburgh at Pittsburgh
FY2016$270,551P50CA121973 - Biomarkers of the Proinflammatory Response and Elements of Immune Suppression
University of Pittsburgh at Pittsburgh
FY2015$272,582P50CA121973
Congress activity
Updated 23 Oct 2026
174 congress contributions (2005–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 63: Intratumoral Candida albicans associates with hypoxia and poor outcomes in non small cell lung cancer (NSCLC).
AACR Annual Meeting
AACR2026Co-author - Abstract 7305: Evaluating the unfolded protein response as a therapeutic target in clear cell renal cell carcinoma patients
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanoma.
Journal for immunotherapy of cancer
Article2026 - Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.
Nature medicine
Clinical Trial2026 - Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial.
Journal for immunotherapy of cancer
Clinical Trial2026 - Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.
Nature medicine
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainArticle1,321 citations2018
- 02Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combinationReview1,102 citations2016
- 03Prognostic significance of autoimmunity during treatment of melanoma with interferonArticle508 citations2011
- 04
- 05
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ahmad-tarhini-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗
Editorial & leadership roles
journal and society appointments- Chair
scientific committee, Oncology Research Information Exchange Network (ORIEN)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Oncologic Sciences
USF Morsani College of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancernetwork.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Melissa Alsina, MD
H. Lee Moffitt Cancer Center & Research Institute
Alberto Chiappori, MD
H. Lee Moffitt Cancer Center & Research Institute
Richard Kim, MD
H. Lee Moffitt Cancer Center & Research Institute
Jedd Wolchok, MD
Weill Cornell Medicine
Frank Hodi, MD
Dana-Farber Cancer Institute
Omid Hamid, MD
The Angeles Clinic and Research Institute
Mario Sznol, MD
University of Miami Miller School of Medicine